Abstract
This commentary discusses the article by Low and colleagues, who studied the effect of terazosin in women with lower urinary tract symptoms (LUTS) and an International Prostate Symptom Score (IPSS) ≥8. Terazosin therapy significantly improved IPSS quality-of-life scores and King's Health Questionnaire scores. These findings might seem surprising, because previous studies have shown that α-adrenoreceptor antagonists are not effective in women with overactive bladder, which is considered the most common form of LUTS in females. Many women have voiding symptoms, however, and the inclusion criteria in this study resulted in a different population profile compared with those of other studies of female LUTS. The mechanism behind the effect of terazosin is unclear. Without urodynamic characterization, it cannot be established whether patients in the study were obstructed, or whether the effect of terazosin was related to a decrease in bladder outflow resistance.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Abrams P et al. (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 21: 167–178
Irwin DE et al. (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50: 1306–1314
Gotoh M et al. (2006) Pathophysiology and subjective symptoms in women with impaired bladder emptying. Int J Urol 13: 1053–1057
Ruggieri MR Sr et al. (2005) Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction. J Urol 174: 1743–1748
Robinson D et al. (2007) A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. BJU Int 100: 840–845
Kaplan SA et al. (2006) Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 296: 2319–2328
Low BY et al. (2008) Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial. J Urol 179: 1461–1469
Kawabe K et al. (2006) Silodosin, a new alpha1A-adrenoreceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 98: 1019–1024
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Andersson, KE. Are female lower urinary tract symptoms alleviated by α-adrenoreceptor antagonists?. Nat Rev Urol 5, 586–587 (2008). https://doi.org/10.1038/ncpuro1224
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpuro1224
